Literature DB >> 2006757

Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs.

M Bo1, F Bonino, M Neirotti, M Gottero, L Pernigotti, M Molaschi, F Fabris.   

Abstract

The effects on the coagulative and rheologic pattern of two lipid-lowering drugs, bezafibrate and simvastatin, were studied in 36 hypercholesterolemic subjects. Patients were randomly divided into two groups (18 subjects each) and received bezafibrate R 400 mg/day or simvatatin 10-40 mg/day over a twelve week period. Besides a decrease in plasma fibrinogen and fibrinopeptide A (p less than 0.001 both), bezafibrate induced a reduction of factor VIIc and VIIIc activity (p less than 0.001 both), while antithrombin 3 activity was increased (p less than 0.001) and the hemorheologic pattern was greatly improved (p less than 0.001). Simvastatin caused a slight decrease in factor VIIIc activity and a moderate reduction of beta-thromboglobulin. The efficacy of bezafibrate in reducing the activation of the coagulative cascade and improving the hemorheologic pattern has been confirmed; the peculiar triglycerides- and fibrinogen-lowering effect of the drug, not observed with simvastatin, could be responsible for these modifications.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2006757     DOI: 10.1177/000331979104200204

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  5 in total

Review 1.  Choosing the right lipid-regulating agent. A guide to selection.

Authors:  J A Farmer; A M Gotto
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

Review 2.  Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.

Authors:  K L Goa; L B Barradell; G L Plosker
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

Review 3.  Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.

Authors:  Robert Krysiak; Boguslaw Okopień; Zbigniew Herman
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  LDL-apheresis: technical and clinical aspects.

Authors:  Rolf Bambauer; Carolin Bambauer; Boris Lehmann; Reinhard Latza; Ralf Schiel
Journal:  ScientificWorldJournal       Date:  2012-04-30

5.  Rosuvastatin Reduces Blood Viscosity in Patients with Acute Coronary Syndrome.

Authors:  Lae-Young Jung; Sang-Rok Lee; Jin-Mu Jung; Yi-Shik Kim; Sun-Hwa Lee; Kyoung-Suk Rhee; Jei-Keon Chae; Dong-Hwan Lee; Dal-Sik Kim; Won-Ho Kim; Jae-Ki Ko
Journal:  Korean Circ J       Date:  2016-03-21       Impact factor: 3.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.